Voronoi, Inc. · KRX:310210
Voronoi — Non-Deal Roadshow (December 2025)
47 slides from Voronoi's roadshow presentation, Dec 4, 2025
Slide 1: IR BOOK
Creating Novel Therapeutics By People With Excellent Expertise In Drug Design IR BOOK December 4, 2025
Slide 2: Disclaimer
Investor Relations 2025 Disclaimer The purpose of this document is to explain the research activities, management planning, and other matters of and pertaining to Voronoi, its affiliates, and related companies (hereinafter collectively referred to as the “Company”), to shareholders, investors, and a
Slide 3: VORONOI. Overview
Investor Relations 2025 VORONOI. Overview Company Overview Company Structure Establishment Feb 2015 (KOSDAQ IPO in Jun 2022) “Bio –Tech Cluster” Chief Executive Officer Daekwon Kim, Hyuntae Kim Boston SongDo S 18th F, Songdogwahak-ro 32, Yeonsu-gu, Incheon, Headquarters Republic of Korea 21984 Medch
Slide 4: VORONOI. Pipeline
Investor Relations 2025 VORONOI. Pipeline Clinical Phase Drug Company Indication Target Pre-clinical Phase 1 Phase 2 Phase 3 EGFR del19/C797S, EGFR L858R/C797S EGFR del19, EGFR L858R (Brainmetastasis) Non-small cell lung cancer VRN11 (NSCLC) EGFR uncommon(2L setting) EGFRdel19, L858R, uncommon EGFR
Slide 5: Content
Creating Novel Therapeutics By People With Excellent Expertise In Drug Design CONTENT 1. VRN11. EGFR NSCLC Targeted Therapy 2. VRN10. HER2+ Breast Cancer Targeted Therapy
Slide 6: VRN11. EGFR NSCLC Targeted Therapy
Creating Novel Therapeutics By People With Excellent Expertise In Drug Design VRN11. EGFR NSCLC Targeted Therapy 1. VRN11. Upcoming Development Milestones 2. Comparison of VRN11-Osimertinib 3. EGFR NSCLC Landscape 4. Phase 1a(Dose escalation) clinical trial design 5. Efficacy of 2nd line treatment 6
Slide 7: VRN11. Upcoming Development Milestones
Investor Relations 2025 VRN11. Upcoming Development Milestones Target: Accelerated Approval Filing for EGFR C797S NSCLC Target: Initiation of a Head-to-Head Comparative Clinical Trial for 1L EGFR NSCLC Ph.1a Dose escalation (Ongoing) VORONOI _ 7
Slide 8: Comparison of VRN11-Osimertinib (1) Efficacy in Brain Metastasis①
Investor Relations 2025 Comparison of VRN11-Osimertinib (1) Efficacy in Patients with Brain Metastasis① VRN11 has established the world’s first human PoC data showing 200% brain penetration, compared to 20% for osimertinib Brain Permeability(Kp,uu,brain/Rat)1 Brain Permeability in patients(Kpuu,CSF)
Slide 9: Comparison of VRN11-Osimertinib (1) Efficacy in Brain Metastasis②
Investor Relations 2025 Comparison of VRN11-Osimertinib (1) Efficacy in Patients with Brain Metastasis② 100% Disease Control Rate(DCR)in brain metastatic patients treated beyond the minimum expected effective dose Confirmed case of complete response (CR) in brain metastatic patient Clinical Benefit
Slide 10: Comparison of VRN11-Osimertinib (2) Selectivity
Investor Relations 2025 Comparison of VRN11-Osimertinib (2) Selectivity: “Maximizing Efficacy & Safety” [Comparison of VRN11-Osimertinib] Selectivity Efficacy and Toxicity Changes(Δ) with Increasing Dose Efficacy High-selectivity drug Low-selectivity drug Osimertinib VRN11 Δ: Difference between valu
Slide 11: Comparison of VRN11-Osimertinib (3) Efficacy & Safety
Investor Relations 2025 Comparison of VRN11-Osimertinib (3) Efficacy & Safety VRN11 demonstrated superior efficacy and a favorable safety profile compared to Osimertinib Efficacy 400mg 320mg Osimertinib4 80mg 160mg ORR 67% 87% 240mg Best % change -42% -54% in Target lesion size(mean) G≥3 TEAE 60% 63
Slide 12: Comparison of VRN11-Osimertinib (4) Safety①
Investor Relations 2025 Comparison of VRN11-Osimertinib (4) Safety① Anticancer efficacy confirmed at ≥40 mg in phase 1, and no drug-related Grade 3 or higher observed up to 400 mg (10-fold dose increase) Safety profile of VRN11 observed in phase 1a study (As of 2025.10) Improved safety compared with
Slide 13: Comparison of VRN11-Osimertinib (4) Safety②
Investor Relations 2025 Comparison of VRN11-Osimertinib (4) Safety② Safety Comparison(Osimertinib1 vs VRN11) Osimertinib VRN11 Brain Permeability Brain Permeability 20~30% ≥100% …mg 0% 400mg X5 0% 320mg ≥20 X 240mg 14 % ≥100 X 0% 240mg 160mg 25 % 0% 160mg Approved Dose 80mg 11 % 0% 80mg Efficacy-Mat
Slide 14: EGFR NSCLC Landscape
Investor Relations 2025 EGFR NSCLC Landscape EGFR C797S accounts for ~10% of Osimertinib resistance, and Approximately 30–50%of resistance mechanisms to osimertinibremain unknown EGFR del19, L858R, C797S mutations and SOC (including EGFR TKIs) refractory/resistant patients EGFR Non-small cell lung c
Slide 15: Phase 1a (Dose escalation) clinical trial design
Investor Relations 2025 Phase 1a(Dose escalation) clinical trial design A global Phase 1 clinical trial is ongoing in Taiwan and Korea (including Hong Kong and Australia) Phase 1a Highlights(As of 2025.10) Phase 1a clinical trials design Key Eligibility Criteria Characteristics 10 – 400 mg QD n = 54
Slide 16: Efficacy of 2nd line treatment
Efficacy of 2nd line treatment (Patients with acquired EGFR C797S mutation)
Slide 17: Efficacy in Patients with EGFR C797S Mutation
Investor Relations 2025 Efficacy in Patients with EGFR C797S Mutation As a global first in precision medicine targeted therapy, promising therapeutic efficacy(ORR 75%, 3/4 pts) was observed in the phase 1a (dose escalation) study without any Grade 3 or higher adverse events. Moreover, efficacy was e
Slide 18: Phase 1 Comparison with Competitors Targeting EGFR C797S
Investor Relations 2025 Phase 1 Comparison with Competitors Targeting EGFR C797S Phase1a VRN11 Silevertinib(BDTX-1535)* 40mg 80mg 160mg Efficacy 240mg Dose, mg QD EGFR Mutation ✓ Up to 240mg patients(EGFR C797S), ORR 75%(3/4) ✓ Up to 200mg patients(EGFR C797S), ORR 25%(1/4) Ongoing Ongoing MTD (ph2)
Slide 19: Accelerated Approval Strategy Based on Efficacy in EGFR C797S Mutation
Investor Relations 2025 Accelerated Approval Strategy Based on Efficacy in EGFR C797S Mutation Treatment response rate for the EGFR C797S mutation Accelerated Approval Target for EGFR C797S Mutant NSCLC Chemotherapy(2L)1 VRN11 Tumor size(%) 40~240mg patients, ORR 75%(3/4) mPFS 4.2months Tagrisso VRN
Slide 20: #Case: Efficacy in Patients with EGFR C797S Mutation
Investor Relations 2025 #Case: Efficacy in Patients with EGFR C797S Mutation Confirmed therapeutic efficacy against the EGFR C797S mutation in 40 mg to 240 mg cohorts ( cohorts above 240 mg ongoing) ✓ 40mg Case Report: EGFR L858R/R776H/C797S Baseline and Treatment History Lung, brain, and pleural me
Slide 21: #Case: Efficacy in Patients with EGFR C797S Mutation
Investor Relations 2025 #Case: Efficacy in Patients with EGFR C797S Mutation ✓ 160mg Case Report: EGFR Del19/C797S Baseline C2D1 PR Baseline C2D1 CR non-target lesion Target lesion Right lung Brain 1, 2 ✓ 240mg Case Report: EGFR Del19/C797S Baseline C2D1 PR Baseline C2D1 PR non-target lesion Target
Slide 22: Efficacy of 2nd line treatment
Efficacy of 2nd line treatment (Patients Resistant to First-Line EGFR Therapy)
Slide 23: Simulation of cancer cure rate (2L+; EGFR primary mutation+unknown)
Investor Relations 2025 Simulation of cancer cure rate(2L+; EGFR primary mutation+unknown) Tumor size(%) 100 Tagrisso(80mg) VRN11 Dosing stop Dosing start Tagrisso (D+unknown) “Difference of VRN11-Tagrisso efficacy” 80mg (D) +Unknown 50 SD VRN11 80mg (D+unknown) Tagrisso efficacy (D) PR VRN11 160mg
Slide 24: Comparison of VRN11 and Osimertinib
Investor Relations 2025 Comparison of VRN11 and Osimertinib Among 21 patients with EGFR-mutant NSCLC who have received third-line or later therapies, 18 patients are still in treatment. Based on preliminary observations, mPFS exceeding that of osimertinib(4.07 months) is anticipated VRN11 Tagrisso(O
Slide 25: #Case: VRN11 80mg
Investor Relations 2025 #Case: VRN11 80mg Phase 1a. Dose escalation ✓ 80mg Case Report: EGFR Del19(80mg→160mg) Baseline and Treatment History VRN11 Treatment 400mg > 10 months (on-treatment) Pleura metastasis • Lung lesion: 47.37% tumor reduction Two prior systemic treatments including 320mg • Pleur
Slide 26: #Case: VRN11 160mg, 240mg
Investor Relations 2025 #Case: VRN11 160mg, 240mg Phase 1a. Dose escalation ✓ 240mg Case Report: EGFR L858R Baseline and Treatment History VRN11 Treatment 400mg EGFR L858R mutation • Target lesions: 43% reduction(after 4 weeks) 320mg Best response: PR Prior treatment: 10 prior treatments No DLT Safe
Slide 27: Unmet needs for SOC resistant/refractory patients
Investor Relations 2025 Unmet needs for SOC (including EGFR TKIs) resistant/refractory patients Current therapies show limited efficacy and safety in standard-treatment–resistant/refractory patients Strong disease control observed in heavily pretreated patients supports the expectation of improved o
Slide 28: Potential of 1st line treatment
Potential of 1st line treatment
Slide 29: Persister Cancer Cell, Treatment Resistance and PFS
Investor Relations 2025 Persister Cancer Cell, Treatment Resistance and PFS The treatment rate reflects the remaining tumor cells. Fewer residual tumor cells are associated with a lower chance of developing resistance or alternative signaling pathways, resulting in prolonged progression-free surviva
Slide 30: Reinterpretation of IC50 data
Investor Relations 2025 Reinterpretation of IC50 data Treatment Potency (Treatment Rate) = f {(Binding affinity) × (Drug concentration in the system)} PFS Prediction Enabled by PK-Based Target Engagement Modeling Target engagement ratio VRN11 Osimertinib VRN11 EGFR mutations 320mg 80mg /Osimertinib
Slide 31: Ctrough/IC50-PFS relationship (ALK, EGFR)
Investor Relations 2025 Ctrough/IC50- PFS relationship(ALK, EGFR) ALK fusion NSCLC case 70 70 ✓ Binding Probability 100 (Concentration) Ctrough,ss/IC50 ratio 𝑪𝒕𝒓𝒐𝒖𝒈𝒉,𝒔𝒔,𝒇𝒓𝒆𝒆 35 35 Month IC50(nM) 10 1 𝑰𝑪𝟓𝟎 0 0 crizotinib brigatinib alectinib lorlatinib ✓ Binding Affinity Crizotinib…
Slide 32: Comparison of PFS of targeted therapies
Investor Relations 2025 Comparison of PFS of targeted therapies Comparison of PFS of targeted therapies(ALK) Comparison of PFS of targeted therapies(EGFR) 3rd gen 1st gen 1st gen ALK Gefitinib 3rd gen Crizotinib Lorlatinib EGFR Erlotinib Osimertinib mPFS 10.9m 72m~NR BBB permeability 1~3% mPFS 9.7m
Slide 33: Market size
Market size
Slide 34: EGFR NSCLC Market size
Investor Relations 2025 EGFR NSCLC Market size EGFR NSCLC Market Analysis PFS improvement Each EGFR mutation specific differentiation may grow market additionally EGFR DC, LC Annual EGFR TKI sales • “First/Best-in class Drug” USD 14.2bn(2032 expected) • No treatment option available Uncommon • Aimin
Slide 35: VRN10. HER2+ Breast Cancer Targeted Therapy
Creating Novel Therapeutics By People With Excellent Expertise In Drug Design VRN10. HER2+ Breast Cancer Targeted Therapy 1. HER2+ Breast Cancer Treatment Guideline 2. HER2+ TKI Competitive Landscape 3. Clinical Data Comparison 4. Antitumor Activity in HER2 Solid Tumors Observed from the Starting Do
Slide 36: HER2 positive Breast Cancer Treatment Guideline
Investor Relations 2025 HER2 positive Breast Cancer Treatment Guideline VRN10 to overcome limitations of existing treatment options Trastuzumab+ Tucatinib+ Standard 1L Pertuzumab+ 2L T-dxd(Enhertu) 3L+ Trastuzumab+ of Care Docetaxel Capecitabine mPFS 28.8 months Results of mPFS 18.5 months mPFS 7.6
Slide 37: HER2 positive TKI Competitive Landscape
Investor Relations 2025 HER2 positive TKI Competitive Landscape VRN10 Zongertinib Neratinib ZN-A-1041 Tucatinib HER2 selectivity over EGFR +++ +++ - + +++ Potency to resistant mutants +++ +++ + + Intracranial efficacy +++ - - +++ + Binding mode Covalent Covalent Covalent Non-covalent Non-covalent GS
Slide 38: Clinical Data Comparison (Enhertu vs Zongertinib)
Investor Relations 2025 Clinical Data Comparison (Enhertu vs Zongertinib) [HER2 NSCLC] T-Dxd vs Zongertinib Drug name T-Dxd1 Zongertinib2 (Clinical trial) (DESTINY-Lung02) (Beamion LUNG-1) [HER2-altered Breast Cancer] Efficacy(previously treated patients)4 ORR 49% 71% mPFS 9.9 months 12.4 months 17%
Slide 39: Clinical Data Comparison (VRN10 vs Zongertinib)
Investor Relations 2025 Clinical Data Comparison (VRN10 vs Zongertinib) Phase1a. Dose escalation(Monotherapy) VRN10. Pharmacokinetics(PK) 640mg 480mg 320mg 240mg 160mg VRN101099, unbound PK 100 80 mg QD patient A 80mg 80 mg QD patient B Plasma free drug (nM) 10 pHER2 IC90 ✓ Grade≥3 TRAE(LLE, etc.) 1
Slide 40: Antitumor Activity in HER2 Solid Tumors Observed from the Starting Dose
Investor Relations 2025 Antitumor Activity in HER2 Solid Tumors Observed from the Starting Dose in Phase 1a Study Demonstrated Antitumor Activity in 2/2 T-DXd–Refractory and 3/3 HER2-Mutant Patients Phase1a. Dose escalation(Monotherapy) VRN10. Efficacy 640mg 480mg 320mg -24.2 -26.7 -28.6 240mg 160mg
Slide 41: Clinical Data Comparison (HER2 SNV mutation; VRN10 vs T-DXd vs Zongertinib)
Investor Relations 2025 Clinical Data Comparison (HER2 SNV mutation; VRN10 vs T-DXd vs Zongertinib) T-DXd(NSCLC) Zongertinib VRN10 ✓ S310F PR 50% (3/6) ✓ S310F (80 mg): -26.7% ✓ S310Y PR 0% (0/4) ✓ S310Y (160 mg): -28.6% ✓ L755P Data 없음(n=3) ✓ V777L (160mg): -29.7%* ✓ HER2 SNV PR 33% (4/12) ✓ S310F
Slide 42: #Case Study(80mg)
Investor Relations 2025 #Case Study(80mg) ✓ 80mg, Pancreas(AU001-001) ✓ 80mg, Gastric(AU002-003) Baseline and Treatment History Baseline and Treatment History VRN10 80mg VRN10 80mg C1D1 C3D1 Primary site: Pancreas Primary site: Gastric HER2 biomarker: S310F HER2 IHC2+/ DISH- Prior systemic Tx: 3 Pri
Slide 43: #Case Study(160mg)
Investor Relations 2025 #Case Study(160mg) ✓ 160mg, Lung(KR004-003) TL1 (Liver) TL2 (Breast) TL3 (Lung) 76.3mm 25.8mm Baseline and Treatment History Baseline Baseline Primary site: Lung HER2 biomarker: S310Y Prior systemic Tx: 3 13.1mm -T-DXd 65.1mm 16.2mm VRN10 Treatment Best response(C3D1): C3D1 S
Slide 44: #Case Study(160mg)
Investor Relations 2025 #Case Study(160mg) ✓ 160mg, Breast(KR004-001) TL1 (Liver) TL2 (Liver) Baseline and Treatment History 56.6mm Baseline Primary site: Breast HER2 biomarker: V777L 16.1mm Prior systemic Tx: 7 T-Dxd VRN10 Treatment 40.8mm Best response(C3D1): C3D1 Stable Disease(Overall -24.2%) Cy
Slide 45: Safety
Investor Relations 2025 Safety Superior safety profile compared to competitors observed from the starting dose Phase1a. Dose escalation(Monotherapy) VRN10. Safety(Comparison of Zongertinib Safety) VRN10 Zongertinib 640mg Event (%) All Grade≥3 All Grade≥3 All Grade≥3 80mg (n=3) 160mg (n=3) 120mg (n=7
Slide 46: Phase 1a Trial Design
Investor Relations 2025 Phase 1a Trial Design Ongoing global phase 1 trial in South Korea and Australia, with first patient dosed in Q1 2025 Combination trial planned from phase 1b onward Phase 1a Highlights Phase 1 clinical trial design Key Eligibility Criteria Ph1a dose escalation Ph1b dose escala
Slide 47: Thank You
Creating Novel Therapeutics By People With Excellent Expertise In Drug Design Thank You